Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Fazaclo

Known as: CLOZAPINE (FAZACLO) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
2012
2012
  • 2012
  • Corpus ID: 20426481
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR… 
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
2012
2012
OBJECTIVE To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking… 
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2008
2008
AbstractBackground: This study compared the bioequivalence of FazaClo® (clozapine orally disintegrating tablets) 100 mg to… 
Review
2007
Review
2007
  • R. Ganguli
  • The Journal of clinical psychiatry
  • 2007
  • Corpus ID: 24009514
Compared with the general population, individuals with schizophrenia demonstrate an increased prevalence of obesity. While most… 
  • table 1
  • table 2
2007
2007
OBJECTIVE Interventions improving adherence to antipsychotic medication are needed. The present study examined the effects on… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Highly Cited
2006
Highly Cited
2006
BACKGROUND The main objective was to assess the efficacy of a weight management program designed for outpatients taking… 
  • table 1
  • table 2
  • table 3
  • figure 1
Review
2005
Review
2005
Patients with schizophrenia are at significantly increased risk for infection with human immunodeficiency virus (HIV), hepatitis…